Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Boehringer Ingelheim
Chubb
Dow
Johnson and Johnson
McKinsey
Federal Trade Commission
Cerilliant
McKesson

Generated: June 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,787,161

« Back to Dashboard

Which drugs does patent 6,787,161 protect, and when does it expire?

Patent 6,787,161 protects PICATO and is included in one NDA.

This patent has seventeen patent family members in fifteen countries.
Summary for Patent: 6,787,161
Title: Anti-cancer compounds
Abstract:This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s): Aylward; James Harrison (Queensland, AU)
Assignee: Peplin Biotech Pty. Ltd. (Fortitude Valley, AU)
Application Number:09/888,178
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,787,161
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 6,787,161

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ACTINIC KERATOSIS ➤ Sign Up
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF ACTINIC KERATOSIS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,787,161

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPO8640Aug 19, 1997

Non-Orange Book US Patents Family Members for Patent 6,787,161

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,452 Anti-cancer compounds ➤ Sign Up
7,410,656 Anti-cancer compounds ➤ Sign Up
6,844,013 Methods of stimulating the immune system ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Accenture
Fish and Richardson
Fuji
Queensland Health
Mallinckrodt
QuintilesIMS
Chinese Patent Office
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.